Emergent BioSolutions (EBS) Income towards Parent Company (2011 - 2026)
Emergent BioSolutions (EBS) posted Income towards Parent Company of -$180.2 million for Q2 2026, down 2750.0% on a QoQ basis from $6.8 million in Q1 2026, and down 1401.67% year-over-year from $13.8 million in Q2 2025.
Powered by 
Analysis
Emergent BioSolutions (EBS) Income towards Parent Company (2011 - 2026) Analysis & Trends
Emergent BioSolutions has reported Income towards Parent Company for 16 years, with the latest figure at -$180.2 million in Q2 2026.
- On a quarterly basis, Income towards Parent Company fell 1401.67% year-over-year to -$180.2 million in Q2 2026; TTM through Jun 2026 was -$176.8 million, a 226.74% decrease from a year earlier, with the FY2025 full-year figure at $52.6 million, up 127.6% from the prior year.
- Income towards Parent Company was -$180.2 million for Q2 2026 at Emergent BioSolutions, down from $6.8 million in the prior quarter.
- The five-year high for Income towards Parent Company was $114.8 million in Q3 2024, with the low at -$283.1 million in Q2 2024.
- Average Income towards Parent Company over 5 years is -$71.4 million, with a median of -$52.0 million recorded in 2023.
- The sharpest annual moves came in 2023 and 2025: Income towards Parent Company sank 4932.43% in 2023, then surged 655.56% in 2025.
- Over 5 years, Income towards Parent Company stood at -$67.0 million in 2022, then advanced by 26.12% to -$49.5 million in 2023, then surged by 36.77% to -$31.3 million in 2024, then slumped by 74.44% to -$54.6 million in 2025, then plunged by 230.04% to -$180.2 million in 2026.
- The last three Income towards Parent Company figures came in at -$180.2 million (Q2 2026), $6.8 million (Q1 2026), and -$54.6 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 649.47 Bn | 628.71 Bn | 17.26 Bn |
| 2 | AbbVie | 467.46 Bn | 460.93 Bn | 12.70 Bn |
| 3 | Merck | 369.31 Bn | 362.22 Bn | 12.21 Bn |
| 4 | Novartis Ag | 269.03 Bn | 261.74 Bn | 11.24 Bn |
| 5 | Pfizer | 158.11 Bn | 146.71 Bn | 10.94 Bn |
| 6 | Bristol Myers Squibb | 127.96 Bn | 116.89 Bn | 9.25 Bn |
| 7 | Sanofi | 51.83 Bn | 44.86 Bn | 10.79 Bn |
| 8 | BeOne Medicines | 41.33 Bn | 36.23 Bn | 1.53 Bn |
| 9 | Revolution Medicines | 41.30 Bn | 41.30 Bn | - |
| 10 | Emergent BioSolutions | 335.50 Mn | 194.60 Mn | 137.20 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -180.20 Mn |
| Mar 31, 2026 | 6.80 Mn |
| Dec 31, 2025 | -54.60 Mn |
| Sep 30, 2025 | 51.20 Mn |
| Jun 30, 2025 | -12.00 Mn |
| Mar 31, 2025 | 68.00 Mn |
| Dec 31, 2024 | -31.30 Mn |
| Sep 30, 2024 | 114.80 Mn |
| Jun 30, 2024 | -283.10 Mn |
| Mar 31, 2024 | 9.00 Mn |
| Dec 31, 2023 | -49.50 Mn |
| Sep 30, 2023 | -263.40 Mn |
| Jun 30, 2023 | -261.40 Mn |
| Mar 31, 2023 | -186.20 Mn |
| Dec 31, 2022 | -67.00 Mn |
| Sep 30, 2022 | -87.10 Mn |
| Jun 30, 2022 | -56.40 Mn |
| Mar 31, 2022 | -3.70 Mn |
| Dec 31, 2021 | 177.90 Mn |
| Sep 30, 2021 | -32.70 Mn |
API Access
Emergent BioSolutions Income towards Parent Company API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=income-towards-parent-company&ticker=EBS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "income-towards-parent-company", "ticker": "EBS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=income-towards-parent-company&ticker=EBS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();